Taisho Pharmaceutical Holdings Stock Book Value Per Share
| TAIPYDelisted Stock | USD 14.00 0.00 0.00% |
Taisho Pharmaceutical Holdings fundamentals help investors to digest information that contributes to Taisho Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Taisho Pink Sheet. The fundamental analysis module provides a way to measure Taisho Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Taisho Pharmaceutical pink sheet.
Taisho |
Taisho Pharmaceutical Holdings Company Book Value Per Share Analysis
Taisho Pharmaceutical's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Taisho Pharmaceutical Book Value Per Share | 2,413 X |
Most of Taisho Pharmaceutical's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Taisho Pharmaceutical Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
CompetitionIn accordance with the recently published financial statements, the book value per share of Taisho Pharmaceutical Holdings is about 2.41 K times. This is 142048.26% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The book value per share for all United States stocks is 24.93% lower than that of the firm.
Taisho Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Taisho Pharmaceutical's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Taisho Pharmaceutical could also be used in its relative valuation, which is a method of valuing Taisho Pharmaceutical by comparing valuation metrics of similar companies.Taisho Pharmaceutical is currently under evaluation in book value per share category among its peers.
Taisho Fundamentals
| Return On Equity | 0.0345 | |||
| Return On Asset | 0.0183 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 1.27 B | |||
| Shares Outstanding | 327.94 M | |||
| Price To Earning | 20.67 X | |||
| Price To Book | 0.57 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 268.2 B | |||
| Gross Profit | 163.83 B | |||
| EBITDA | 42.81 B | |||
| Net Income | 13.12 B | |||
| Cash And Equivalents | 276.54 B | |||
| Cash Per Share | 843.28 X | |||
| Current Ratio | 6.21 X | |||
| Book Value Per Share | 2,413 X | |||
| Cash Flow From Operations | 28.51 B | |||
| Earnings Per Share | 0.49 X | |||
| Number Of Employees | 9.13 K | |||
| Beta | 0.26 | |||
| Market Capitalization | 3.35 B | |||
| Total Asset | 888.16 B | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 888.16 B | |||
| Last Dividend Paid | 50.0 |
About Taisho Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Taisho Pharmaceutical Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Taisho Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Taisho Pharmaceutical Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Taisho Pink Sheet
If you are still planning to invest in Taisho Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taisho Pharmaceutical's history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |